Symbols

STAA

Staar Surgical·NASDAQ

--(--)

STAA fundamentals

STAA Q4 2025 Earnings

Staar Surgical (STAA) released its earnings on Mar 3, 2026: revenue was 57.80M (YoY +18.08%), missed estimates; EPS was -0.2 (YoY +61.05%), missed estimates.

Revenue / YoY

57.80M

+18.08%

EPS / YoY

-0.2

+61.05%

Report date

Mar 3, 2026

STAA Earnings Call Summary for Q4,2025

China Recovery Drives Growth: 2025 in-market EVO ICL demand rebounded mid-single-digit, with 2026 targeting normalized distributor inventory and net sales growth.
U.S. Expansion Accelerates: EVO's expanded age range adds 8M candidates, Q4 U.S. sales +18% YoY, driven by surgeon adoption of lens-based procedures.
Profitability Focus: 2026 targets profitability with cost discipline, gross margin slightly lower due to Swiss manufacturing costs but offset by higher ASPs.
Innovation Momentum: EVO+ launch in China with premium ASPs, Lioli injector rollout in EMEA, and Swiss manufacturing supporting supply chain resilience.

Earnings

EPS

Revenue

Revenue & Expenses

STAA has released its 2025 Q4 earnings report, with revenue of 57.80M, reflecting a YoY change of 18.08%, and net profit of -18.31M, showing a YoY change of 46.51%. The Sankey diagram below clearly presents STAA's revenue sources and cost distribution.

Key Indicators

Staar Surgical (STAA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Staar Surgical (STAA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Staar Surgical (STAA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Staar Surgical (STAA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown